Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
L. Cortesi
Observed name:
Lisa Cortesi
Institutions:
University of Modena and Reggio Emilia,
Azienda Sanitaria Unità Locale di Reggio Emilia,
Azienda Ospedaliero-Universitaria di Modena
Observed institutions:
University of Modena and Reggio Emilia,
Azienda Sanitaria Unità Locale di Reggio Emilia,
Azienda Ospedaliero-Universitaria di Modena
ORCID:
0000-0001-8950-8561
Observed ORCID:
0000-0001-8950-8561
OpenAlex ID:
A5007986466
Vicarious, extended and imagined intergroup contact: A review of interventions based on indirect contact strategies applied in educational settings
2017
·
Gian Antonio Di Bernardo
, Loris Vezzali
, et al.
·
Greenwich Academic Literature Archive (University of Greenwich)
·
62
Biomarkers of Homologous Recombination Deficiency in the era of PARP inhibitors
2022
·
C. Piombino
, L. Cortesi
·
Annals of Research in Oncology
·
2
PDF
350P Long-term gynaecological safety and benign breast disease on low-dose tamoxifen: 10-year results from the TAM-01 phase III trial
2025
·
A. Carbone
, M. Oliva
, et al.
·
Annals of Oncology
·
1
390P Predictors of outcome with trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (HER2+ aBC): A multicentric, cohort study (DeReal-REST)
2025
·
A. Fabi
, A. Palazzo
, et al.
·
ESMO Open
·
1
PDF
146P HRD/TIL-low high-risk breast cancer is characterized by good prognosis (the RADIMMUNE trial)
2022
·
B. Pellegrino
, A. Llop-Guevara
, et al.
·
Annals of Oncology
·
1
904MO Anthracycline-related cardiotoxicity in breast cancer patients carrying mutational signature of homologous recombination deficiency (HRD)
2022
·
L. Incorvaia
, A. Fiorino
, et al.
·
Annals of Oncology
·
1
1909eP Genitourinary syndrome of menopause in breast cancer patients receiving adjuvant ovarian suppression
2026
·
S. Zaniboni
, G. Grandi
, et al.
·
Annals of Oncology
586P Trend of BRCA testing along 15 years in a population-based cohort of breast cancer patients
2026
·
L. Cortesi
, A. Muzzarelli
, et al.
·
Annals of Oncology
Reply to Letter to the Editor on: A. G. Nerlich, J. C. Dewaal, A. Perciaccante, S. Di Cosimo, L. Cortesi, J. Wimmer, S. T. Donnell, R, Bianucci: Did Michelangelo paint a young adult woman with breast cancer in “The Flood” (Sistine Chapel, Rome)? Breast 2024, 78, 103823 by Dr. Paul Gelinsky
2026
·
S. Di Cosimo
, A.G. Nerlich
, et al.
·
The Breast
362P Beyond BRCA1/2: Integrated germline SNV and CNV profiling defines the genetic landscape of male breast cancer in a large Italian multicenter cohort
2026
·
A. Bucalo
, V. Valentini
, et al.
·
ESMO Open
PDF
514P Medication-driven management and heterogeneous prophylaxis patterns in T-DXd–related emesis. Results of the worldwide HERMIONE-EDUcational project
2026
·
M.E. Cazzaniga
, M.S. Aapro
, et al.
·
ESMO Open
PDF
73P Comprehensive molecular profiling identifies PI3K/AKT alterations and high TMB as clinically relevant biomarkers in male breast cancer
2026
·
V. Valentini
, A. Bucalo
, et al.
·
ESMO Open
366P Mismatch repair deficiency in breast cancer: Clinical features and genetic implications beyond the traditional homologous recombination repair pathway
2026
·
T.D. Bazan Russo
, L. Cortesi
, et al.
·
ESMO Open
PDF
737eP From complexity to clarity: Development of an Italian triple-negative breast cancer patient journey
2026
·
N.M. La Verde
, L. Brogonzoli
, et al.
·
ESMO Open
PDF
406eP Multiple germline pathogenic or likely pathogenic variants in a cohort of breast cancer patients
2026
·
I. Galasso
, S. Zaniboni
, et al.
·
ESMO Open
PDF
314TiP The “Breast cancer RElapsed after adjuvant CDK4/6 inhibitors: Evaluation in the real-world setting (BREAKER)” trial
2026
·
L. Licata
, R. De Sanctis
, et al.
·
ESMO Open
PDF
385P Clinicopathologic features and prognosis of breast cancer in germline ATM and CHEK2 carriers: a monocentric retrospective study
2026
·
F. Siciliano
, E. Zattarin
, et al.
·
ESMO Open
480P Treatment evolution and survival outcomes in advanced triple-negative breast cancer: A real-world cohort study
2026
·
E. Zattarin
, M. Venturelli
, et al.
·
ESMO Open
Abstract PS1-11-28: Prognostic impact of type and location of germline BRCA2 pathogenic or likely pathogenic variants in patients with HR+/HER2- advanced breast cancer: results from the multicenter real-world PAMBRACA study
2026
·
E. Zattarin
, E. Tenedini
, et al.
·
Clinical Cancer Research
Abstract PS3-03-17: Analysis of second breast cancers in BRCA1/2 and other predisposing gene carriers at the Reggio Emilia Hereditary Cancer Center, Italy
2026
·
E. Gasparini
, M. Rotolo
, et al.
·
Clinical Cancer Research
3045eP Association between Mismatch repair (MMR) germline pathogenic variants and breast cancer: Preventive and therapeutic implications from a multicenter cohort study
2025
·
L. Incorvaia
, L. Cortesi
, et al.
·
Annals of Oncology
329P Nine-years results of genetic BRCA1/2 testing and personalized breast cancer screening in Reggio Emilia program
2025
·
L. Cortesi
, G. Moretti
, et al.
·
Annals of Oncology
443P Vaginal erbium laser for the treatment of genitourinary syndrome in premenopausal breast cancer patients
2025
·
S. Zaniboni
, O. Ponzoni
, et al.
·
ESMO Open
118P Mutational and clinical profile comparison between long and poor responders to first-line CDK 4/6 inhibitors
2025
·
B. Medici
, A. Farina
, et al.
·
ESMO Open
PDF
269P Her2-low/HRR proficient early triple negative breast cancer is characterized by good prognosis
2024
·
B. Pellegrino
, C. Tornali
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
27
Citation count:
68
H-index:
2
I10-index:
1
Year
Topic
Type